Psychiatry Research: Neuroimaging
Volume 162, Issue 2 , Pages 159-166 , 28 February 2008

[99mTc]TRODAT-1/[123I]IBZM SPECT studies of the dopaminergic system in Tourette syndrome

  • Wen-Juh Hwang

      Affiliations

    • Department of Neurology, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 70428, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886 6 276 6187; fax: +886 6 237 4285.
    • ,
  • Wei-Jen Yao

      Affiliations

    • Department of Nuclear Medicine, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 70428, Taiwan
    • ,
  • Ying-Kai Fu

      Affiliations

    • Institute of Nuclear Energy Research, 1000 Wunhua Road, Jiaan Village, Longtan Township, Taoyuan County 32546, Taiwan
    • ,
  • An-Shoei Yang

      Affiliations

    • Institute of Nuclear Energy Research, 1000 Wunhua Road, Jiaan Village, Longtan Township, Taoyuan County 32546, Taiwan

Received 31 July 2006 ,Revised 22 March 2007 ,Accepted 8 April 2007.

References 

  1. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003;61:310–315
  2. American Psychiatric Association . In: Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: APA; 1994;p. 101–103
  3. Anca MH, Giladi N, Korczyn AD. Ropinirole in Gilles de la Tourette syndrome. Neurology. 2004;62:1626–1627
  4. Black KJ, Mink JW. Response to levodopa challenge in Tourette syndrome. Movement Disorders. 2000;15:1194–1198
  5. Brooks DJ, Turjanski N, Sawle GV, Playford ED, Lees AJ. PET studies on the integrity of the pre- and post-synaptic dopaminergic system in Tourette syndrome. Advances in Neurology. 1992;58:227–231
  6. Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study. Journal of Clinical Psychiatry. 2001;62:50–56
  7. Butler IJ, Koslow SH, Seifert WE, Caprioli RM, Singer HS. Biogenic amine metabolism in Tourette syndrome. Annals of Neurology. 1979;6:37–39
  8. Camps M, Cortés R, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D2 sites. Neuroscience. 1989;28:275–290
  9. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Transactions on Nuclear Science. 1978;NS25:638–643
  10. Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD. Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naïve children with Tourette's disorder. Psychiatry Research. Neuroimaging. 2004;130:85–95
  11. Cohen DJ, Shaywitz BA, Caparulo B, Young JG, Bowers MB. Chronic, multiple tics of Gilles de la Tourette's disease. CSF acid monoamine metabolites after probenecid administration. Archives of General Psychiatry. 1978;35:245–250
  12. Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 2002;22:31–39
  13. Ernst M, Zametkin AJ, Jons PH, Matochik JA, Pascualvaca D, Cohen RM. High presynaptic dopaminergic activity in children with Tourette's disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 1999;38:86–94
  14. Factor SA, Sanchez-Ramos JR, Weiner WJ. Cocanie and Tourette's syndrome. Annals of Neurology. 1988;23:423–424
  15. Gelernter J, Vandenbergh D, Kruger SD, Pauls DL, Kurlan R, Pakstis AJ, et al. The dopamine transporter protein gene (SLC6A3): primary linkage mapping and linkage studies in Tourette syndrome. Genomics. 1995;30:459–463
  16. George MS, Robertson MM, Costa DC, Ell PJ, Trimble MR, Pilowsky L, et al. Dopamine receptor availability in Tourette's syndrome. Psychiatry Research. Neuroimaging. 1994;55:193–203
  17. Gilbert DL, Sethuraman G, Sine L, Peters S, Sallee FR. Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial. Neurology. 2000;54:1310–1315
  18. Gilbert DL, Christian BT, Gelfand MJ, Shi B, Mantil J, Sallee FR. Altered mesolimbocortical and thalamic dopamine in Tourette syndrome. Neurology. 2006;67:1695–1697
  19. Goetz CG, Pappert EJ, Louis ED, Raman R, Leurgans S. Advantages of a modified scoring method for the Rush Video-Based Tic Rating Scale. Movement Disorders. 1999;14:502–506
  20. Golden GS. The relationship between stimulant medication and tics. Pediatric Annals. 1988;17:405–408
  21. Haber SN, Kowall NW, Vonsattel JP, Bird ED, Richardson EP. Gilles de la Tourette's syndrome. A postmortem neuropathological and immunohistochemical study. Journal of the Neurological Sciences. 1986;75:225–241
  22. Heinz A, Knable MB, Wolf SS, Matochik JA, Pascualvaca D, Cohen RM. Tourette's syndrome: [I-123]β-CIT SPECT correlates of vocal tic severity. Neurology. 1998;51:1069–1074
  23. Hwang WJ, Yao WJ, Wey SP, Shen LH, Ting G. Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation. European Neurology. 2002;47:113–117
  24. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. Journal of Nuclear Medicine. 2004;45:207–213
  25. Hyde TM, Stacey ME, Coppola R, Handel SF, Rickler KC, Weinberger DR. Cerebral morphometric abnormalities in Tourette's syndrome: a quantitative MRI study of monozygotic twins. Neurology. 1995;45:1176–1182
  26. Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology. 1984;34:688–692
  27. Klawans HL, Falk DK, Nausieda PA, Weiner WJ. Gilles de la Tourette's syndrome after long-term chlorpromazine therapy. Neurology. 1978;28:1064–1068
  28. Krause KH, Dresel S, Krause J, Kung HF, Tatsch K, Lochmüller H. Elevated striatal dopamine transporter in a drug naïve patient with Tourette syndrome and attention deficit/hyperactivity disorder: positive effect of methylphenidate. Journal of Neurology. 2002;249:1116–1118
  29. Kumar R, Lang AE. Coexistence of tics and parkinsonism: evidence for non-dopaminergic mechanisms in tic pathogenesis. Neurology. 1997;49:1699–1701
  30. Kung MP, Liu BL, Yang YY, Billings JJ, Kung HF. A kit formulation for preparation of 123I-IBZM: a new CNS D2 dopamine receptor imaging agent. Journal of Nuclear Medicine. 1991;32:339–342
  31. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99 m TRODAT-1. European Journal of Nuclear Medicine. 1996;23:1527–1530
  32. Malison RT, McDougle CJ, van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, et al. [123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. American Journal of Psychiatry. 1995;152:1359–1361
  33. Mesulam MM. Cocaine and Tourette's syndrome. The New England Journal of Medicine. 1986;315:398
  34. Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, et al. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology. 1999;53:371–374
  35. Müller-Vahl KR, Berding G, Brücke T, Kolbe H, Meyer GJ, Hundeshagen H, et al. Dopamine transporter binding in Gilles de la Tourette syndrome. Journal of Neurology. 2000;247:514–520
  36. Müller-Vahl KR, Berding G, Kolbe H, Meyer GJ, Hundeshagen H, Dengler R, et al. Dopamine D2 receptor imaging in Gilles de la Tourette syndrome. Acta Neurologica Scandinavica. 2000;101:165–171
  37. Müller-Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brücke T, et al. Serotonin transporter binding in Tourette syndrome. Neuroscience Letters. 2005;385:120–125
  38. Pappert EJ, Goetz CG, Louis ED, Blasucci L, Leurgans S. Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology. 2003;61:936–940
  39. Peterson BS. Considerations of natural history and pathophysiology in the psychopharmacology of Tourette's syndrome. Journal of Clinical Psychiatry. 1996;57(Suppl. 9):24–34
  40. Peterson BS. Neuroimaging studies of Tourette syndrome: a decade of progress. Advances in Neurology. 2001;85:179–196
  41. Peterson B, Riddle MA, Cohen DJ, Katz LD, Smith JC, Hardin MT, et al. Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. Neurology. 1993;43:941–949
  42. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60:1130–1135
  43. Serra-Mestres J, Ring HA, Costa DC, Gacinovic S, Walker Z, Lees AJ, et al. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP-CIT/SPECT study. Acta Psychiatrica Scandinavica. 2004;109:140–146
  44. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette's syndrome. Archives of General Psychiatry. 1989;46:722–730
  45. Singer HS, Butler IJ, Tune LE, Seifert WE, Coyle JT. Dopaminergic dysfunction in Tourette syndrome. Annals of Neurology. 1982;12:361–366
  46. Singer HS, Hahn IM, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette syndrome. Annals of Neurology. 1991;30:558–562
  47. Singer HS, Wong DF, Brown JE, Brandt J, Krafft L, Shaya E, et al. Positron emission tomography evaluation of dopamine D2 receptors in adults with Tourette syndrome. Advances in Neurology. 1992;58:233–238
  48. Singer HS, Reiss AL, Brown JE, Aylward EH, Shih B, Chee E, et al. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology. 1993;43:950–956
  49. Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR, et al. Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. American Journal of Psychiatry. 2002;159:1329–1336
  50. Stamenkovic M, Schindler SD, Asenbaum S, Neumeister A, Willeit M, Willinger U, et al. No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette's disorder patients: a [123I]β-CIT SPECT study. European Neuropsychopharmacology. 2001;11:69–74
  51. Sweet RD, Brunn RD, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome: effects of alpha-methyl-para-tyrosine and tetrabenazine. Archives of General Psychiatry. 1974;31:857–861
  52. Turjanski N, Sawle GV, Playford ED, Weeks R, Lammerstma AA, Lees AJ, et al. PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. Journal of Neurology, Neurosurgery and Psychiatry. 1994;57:688–692
  53. Wolf SS, Jones DW, Knable MB, Gorey JG, Lee KS, Hyde TM, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science. 1996;273:1225–1227
  54. Wong DF, Singer H, Marenco S, Brown J, Yung B, Yokoi F, et al. Dopamine transporter reuptake sites measured by [C11]WIN 35,428 PET imaging are elevated in Tourette syndrome patients (abstract). Journal of Nuclear Medicine. 1994;35:130P
  55. Wong DF, Singer HS, Brandt J, Shaya E, Chen C, Brown J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. Journal of Nuclear Medicine. 1997;38:1243–1247

PII: S0925-4927(07)00084-4

doi: 10.1016/j.pscychresns.2007.04.006

Psychiatry Research: Neuroimaging
Volume 162, Issue 2 , Pages 159-166 , 28 February 2008

Article Tools

* Image Usage & Resolution